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CXCR2 and CXCR4 antagonistically
regulate neutrophil trafficking
from murine bone marrow
Kyle J. Eash, Adam M. Greenbaum, Priya K. Gopalan, and Daniel C. Link
Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.

Neutrophils are a major component of the innate immune response. Their homeostasis is maintained, in
part, by the regulated release of neutrophils from the bone marrow. Constitutive expression of the chemokine
CXCL12 by bone marrow stromal cells provides a key retention signal for neutrophils in the bone marrow
through activation of its receptor, CXCR4. Attenuation of CXCR4 signaling leads to entry of neutrophils into
the circulation through unknown mechanisms. We investigated the role of CXCR2-binding ELR+ chemokines
in neutrophil trafficking using mouse mixed bone marrow chimeras reconstituted with Cxcr2–/– and WT
cells. In this context, neutrophils lacking CXCR2 were preferentially retained in the bone marrow, a phenotype resembling the congenital disorder myelokathexis, which is characterized by chronic neutropenia.
Additionally, transient disruption of CXCR4 failed to mobilize Cxcr2–/– neutrophils. However, neutrophils
lacking both CXCR2 and CXCR4 displayed constitutive mobilization, showing that CXCR4 plays a dominant
role in neutrophil trafficking. With regard to CXCR2 ligands, bone marrow endothelial cells and osteoblasts
constitutively expressed the ELR+ chemokines CXCL1 and CXCL2, and CXCL2 expression was induced in
endothelial cells during G-CSF–induced neutrophil mobilization. Collectively, these data suggest that CXCR2
signaling is a second chemokine axis that interacts antagonistically with CXCR4 to regulate neutrophil release
from the bone marrow.
Introduction
Neutrophils are an essential component of the innate immune
response and a major contributor to inflammation. Accordingly,
the number of neutrophils in the blood is tightly regulated. Neutrophil homeostasis is maintained through a balance of neutrophil production, release from the bone marrow, and clearance
from the circulation (1). The bone marrow is the primary site of
neutrophil production, requiring that mature neutrophils transmigrate through an endothelial cell barrier to enter the circulation
(2–4). Under basal conditions, less than 2% of the total body of
mature neutrophils is in the circulation (5). Thus, the bone marrow serves as a reservoir for neutrophils that can be rapidly mobilized in response to infection or other stresses.
Major advances in our understanding of the mechanisms
regulating neutrophil release from the bone marrow have come
from the study of the human disease myelokathexis (with kathexis referring to retention; refs. 6–8). Myelokathexis is characterized by neutropenia despite normal to increased numbers of
neutrophils in the bone marrow. It can occur in isolation or as
a component of warts, hypogammaglobulinemia, infections,
myelokathexis (WHIM) syndrome (WS; refs. 9, 10). Genetic
studies have shown that heterozygous mutations of CXCR4
are the most common cause of WS (11). CXCR4 encodes for a
CXC chemokine receptor whose major ligand is CXCL12 (also
referred to as SDF-1; ref. 12). WHIM-associated mutations of
CXCR4 result in the production of a carboxyterminal truncated
receptor that displays impaired internalization and enhanced
signaling, suggesting that excessive CXCR4 signaling may result
in abnormal neutrophil retention in the bone marrow (13–16).
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Conversely, genetic deletion of CXCR4 in murine hematopoietic cells results in constitutive mobilization of neutrophils into
the blood (17–22). Moreover, treatment of humans or mice with
AMD3100, a small-molecule antagonist of CXCR4, causes rapid
neutrophil mobilization (23, 24). Together with the observation
that CXCL12 is constitutively expressed at a high level by bone
marrow stromal cells (25), these data indicate that the CXCR4/
CXCL12 axis provides a key retention signal for neutrophils in
the bone marrow.
Disruption of CXCR4 signaling is an important mechanism
by which neutrophils are mobilized into the circulation under
stress conditions. Treatment with G-CSF, a major mobilizing
cytokine, is associated with decreased CXCL12 expression in the
bone marrow and decreased CXCR4 expression on neutrophils
(5, 26–28). Yet, the mechanisms by which attenuated CXCR4 signaling leads to migration of neutrophils toward the bone marrow venous sinuses and subsequent entry into the circulation are
unclear. Based on their well-characterized role in other aspects
of neutrophil biology (29), we hypothesized that ELR + CXC
chemokines may direct neutrophil migration toward the bone
marrow vascular space, thereby opposing the CXCR4/CXCL12
axis. This chemokine subclass, composed of CXCL1–CXCL3
and CXCL5–CXCL8, is defined by its specificity for neutrophils,
signaling through CXCR1 and CXCR2, and the tripeptide motif
of glutamic acid–leucine–arginine (ELR) N-terminal to the first
cysteine of the CXC motif (12). ELR+ chemokines are potent neutrophil chemoattractants and activators and induce neutrophil
mobilization from the bone marrow when administered exogenously (4, 30–33). Accordingly, Cxcr2–/– mice have a profound
defect in neutrophil emigration to sites of inflammation, as mice
lack Cxcr1 (34). With respect to neutrophil homeostasis, Cxcr2–/–
mice housed under specific pathogen–free (SPF) conditions dis-
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Figure 1
Cxcr2–/– neutrophils are selectively
retained in the bone marrow of mixed
chimeras. (A) Generation of mixed
chimeras. Bone marrow cells from WT
and Cxcr2–/– mice (expressing Ly5.1
and Ly5.2, respectively; 1 × 106 cells
from each) were mixed in a 1:1 ratio
and transplanted into lethally irradiated congenic WT recipients (expressing Ly5.1). Mice were analyzed 6–8
weeks after transplantation. (B) Representative dot plots showing the
contribution of WT and Cxcr2–/– cells
(with and without Ly5.1, respectively)
to neutrophils (Gr-1 hi) in the blood
and bone marrow. (C) Quantitation
of mature neutrophils (Gr-1hiSSChi) in
the blood, bone marrow, and spleen.
(D) NDI was calculated as described
in Methods to estimate the percentage
of total body neutrophils in the blood.
(E) Number of B lymphocytes (B220+)
or T lymphocytes (CD3+) in the blood
(left) and B lymphocytes in the bone
marrow (right). T lymphocyte chimerism was assessed 6 months after
transplantation (n = 3). (F) Number of
WT or Cxcr2–/– CFU in culture (CFU-C)
or CFU-granulocyte (CFU-G) in the
bone marrow (n = 3). n = 27 (blood);
n = 6 (bone marrow and spleen) from
at least 3 independent transplantations, unless otherwise indicated.

play neutrophilia with a myeloid expansion in the bone marrow
and spleen. In contrast, under gnotobiotic conditions, the level
of circulating neutrophils in Cxcr2–/– mice is normal, raising the
possibility that subclinical infections are inducing a stress granulopoiesis response (35–37).
In the present study, we generated mixed bone marrow chimeras reconstituted with WT and Cxcr2–/– cells to study the cellintrinsic role of CXCR2 in neutrophil trafficking. We showed that
Cxcr2–/– neutrophils were selectively retained in the bone marrow,
reproducing a myelokathexis phenotype. CXCR2 was required for
neutrophil mobilization in response to transient CXCR4 inhibition, although the increased release of Cxcr4–/– neutrophils was not
altered in the absence of CXCR2 signals. CXCR2 ligands CXCL1
(also referred to as KC) and CXCL2 (also referred to as MIP-2 and
GROβ) were constitutively expressed in bone marrow endothelium, and CXCL2 expression was induced during G-CSF–induced
neutrophil mobilization. These results suggest that CXCR2 signaling is a second chemokine axis that controls neutrophil release
from the bone marrow by opposing CXCR4 signals.
2424
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Results
Absence of CXCR2 results in abnormal retention of neutrophils in the
bone marrow. Consistent with previous reports (34, 37), we
observed marked neutrophilia in Cxcr2 –/– mice maintained
under SPF conditions (absolute count, Cxcr2–/–, 4.63 ± 1.58 × 106
neutrophils/ml; congenic WT, 0.69 ± 0.06 × 106 neutrophils/ml;
P = 0.04). To determine whether this phenotype was due to a cell
intrinsic effect of a loss of CXCR2 signaling, mixed bone marrow
chimeras were generating by transplanting a 1:1 ratio of WT and
Cxcr2–/– bone marrow cells into irradiated congenic mice (Figure
1A). Blood neutrophil counts in the Cxcr2–/– mixed chimeras were
reduced in comparison with mice reconstituted with WT cells
alone (1.08 ± 0.08 × 106 versus 1.81 ± 0.29 × 106 neutrophils/ml;
P = 0.003), which suggests that the neutrophilia in Cxcr2–/– mice
is the result of a cell-extrinsic mechanism.
In the mixed chimeras, the number of Cxcr2–/– neutrophils in
the blood was reduced compared with that in the bone marrow
(Figure 1, B and C). Whereas 65.3% ± 7.6% of neutrophils in the
bone marrow were derived from Cxcr2–/– cells, only 25.0% ± 3.5%
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Figure 2
CXCR2 deficiency produces a
myelokathexis-like phenotype. (A)
Representative dot plots of mixed
chimera bone marrow showing the
percentage of Gr-1 hiSSChi cells
within the total Gr-1+ myeloid cell
population for WT and Cxcr2–/–
cells. (B) Percent Gr-1 hiSSC hi
cells within the total Gr-1+ myeloid
cell population for n = 7 chimeric
mice from 2 independent transplants. (C) Representative photo
micrographs of sorted WT and
Cxcr2–/– Gr-1+ cells. Scale bars:
20 μm. (D) Manual leukocyte differentials of sorted cells from n = 5
mice from 2 transplants. Blast,
myeloblast; Band, band neutrophil; Seg, segmented neutrophil.
***P < 0.001, 2-way ANOVA.

of neutrophils in the blood were from Cxcr2–/– cells (P < 0.0001).
Of note, the number of neutrophils in the spleen, another reservoir for neutrophils, was comparable between Cxcr2–/– and WT
cells (Figure 1C). Neutrophil trafficking from the bone marrow
was estimated by calculating the percentage of neutrophils in the
blood relative to the total number of neutrophils in the blood,
bone marrow, and spleen (neutrophil distribution index; NDI;
ref. 5). Consistent with previous studies (22, 38), under basal
conditions, 1.84% ± 0.32% of WT neutrophils were present in the
blood (Figure 1D). In contrast, the percentage of Cxcr2–/– neutrophils in the blood was 0.57% ± 0.18% (P = 0.02). No perturbation
in other hematopoietic lineages was observed (Figure 1E), which

indicates that the observed differences in neutrophil chimerism
are not caused by altered engraftment of Cxcr2–/– hematopoietic
stem cells. Consistent with this observation, the number and
cytokine responsiveness of myeloid progenitors in the bone marrow were comparable between WT and Cxcr2–/– cells (Figure 1F).
Myelokathexis is characterized by the accumulation of mature,
often hypersegmented or dysplastic, neutrophils in the bone marrow (10). Consistent with this phenotype, we observed that the
percentage of Gr-1hiSSChi cells — representing the most mature
neutrophils (39) — relative to the total Gr-1+ myeloid cell population was higher for Cxcr2–/– than WT cells (Figure 2, A and B). To
confirm this finding, Cxcr2–/– and WT Gr-1+ myeloid cells were

Figure 3
Mobilization of Cxcr2–/– neutrophils by G-CSF is impaired. (A) Mixed chimeras (n = 5) were given a single injection of G-CSF (125 μg/kg), and the
absolute neutrophil count for each genotype was determined 1.5 hours after injection. (B) G-CSF (125 μg/kg/d, twice daily) was administered to
a separate cohort of n = 5 chimeric mice for 5 days, and blood neutrophils were quantified. (C) Number of WT or Cxcr2–/– Gr-1+SSChi cells in the
bone marrow and spleen after 5 days of G-CSF administration. (D) The calculated NDI after 5 days of G-CSF. †P < 0.05, ‡P < 0.01 versus time 0;
**P < 0.01, ***P < 0.001 versus Cxcr2–/– at the same time point; 2-way ANOVA.
The Journal of Clinical Investigation

http://www.jci.org

Volume 120

Number 7

July 2010

2425

Downloaded on September 23, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/41649

research article

Figure 4
CXCR2 and CXCR4 signals interact antagonistically to regulate neutrophil release. (A) Representative dot plots show cell surface CXCR4
expression of WT and Cxcr2–/– Gr-1+SSChi bone marrow cells from a Cxcr2–/– mixed chimera (right), and cells treated with an isotype-matched
antibody (left), shown as controls. Bar graphs show CXCR4 MFI and percent CXCR4+ cells from n = 5 mice. White bars, WT; black bars, Cxcr2–/–.
(B) Cxcr2–/– mixed chimeras (n = 5) were given a single subcutaneous injection of AMD3100 (5 mg/kg), and neutrophils were quantified at the
indicated times. (C and D) Number of neutrophils in the bone marrow and spleen (C) and NDI (D) at 1 hour after AMD3100 administration (n = 3).
(E and F) MKO (n = 10) and DKO (n = 4) mixed chimeras were established as described in Figure 1. Blood, bone marrow, and spleen neutrophils (E) and NDI (F) were quantified 7 weeks after transplantation. ***P < 0.001, 1-way ANOVA. (G) MKO mixed chimeras (n = 3) were given a
subcutaneous injection of GROβ (100 μg/kg), and the number of WT and Cxcr4–/– neutrophils in the blood was measured after 30 minutes. (B
and G) †P < 0.05, ‡P < 0.01 versus time 0; **P < 0.01, ***P < 0.001 versus WT at the same time point; 2-way ANOVA.

sorted from the bone marrow of the mixed chimeras, and manual
leukocyte differentials were performed. Cxcr2–/– cells showed an
increase in the proportion of highly segmented, occasionally dysplastic-appearing, neutrophils (Figure 2, C and D). Collectively,
these data showed that CXCR2 deficiency results in a myelokathexis-like phenotype with a cell-intrinsic retention of neutrophils
in the bone marrow.
Neutrophil mobilization by G-CSF is impaired in the absence of CXCR2.
Because it is the principal cytokine regulating emergency granulopoiesis (40), we next measured the short-term (1–2 hours) and
long-term (5 days) neutrophil responses to G-CSF in the Cxcr2–/–
mixed chimeras. Consistent with previous reports (5, 22), administration of G-CSF resulted in a 2.3- ± 0.5-fold increase in the blood
of WT neutrophils within 2 hours (Figure 3A). In contrast, there
was no significant increase in Cxcr2–/– neutrophils. After the full
5-day course of G-CSF, a significant increase in total neutrophils
(both WT and Cxcr2–/–) in the blood, bone marrow, and spleen was
observed in the mixed chimeras (Figure 3, B and C, compare with
Figure 1C). Note that there were fewer Cxcr2–/– than WT neutro2426
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phils in the bone marrow because this cohort of mice by chance
had lower engraftment of Cxcr2–/–cells (as measured by B lymphocyte chimerism; data not shown). Neutrophil release, as measured
by the NDI, increased in response to 5-day G-CSF treatment in
both genotypes (Figure 3D, compare with Figure 1D). However,
the percentage of Cxcr2–/– neutrophils in the blood after G-CSF
administration was still significantly lower than that for WT cells.
These data show that maximal blood neutrophil responses to
G-CSF require CXCR2 signaling.
CXCR2 antagonistically regulates CXCR4-mediated neutrophil retention
in the bone marrow. Previous studies have established a dominant
role for CXCR4 signals in the retention of neutrophils in the bone
marrow (20, 22, 41–45). Because CXCR2 signaling has previously
been shown to regulate CXCR4 cell surface expression through
heterologous desensitization and receptor internalization (43,
46), we first assessed CXCR4 expression on Cxcr2–/– neutrophils.
However, cell surface expression of CXCR4 on bone marrow neutrophils was similar between WT and Cxcr2–/– cells (MFI, 107 ± 7
and 100 ± 12, respectively; P = 0.4; Figure 4A), arguing against a
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Figure 5
CXCR2 ligands are produced by bone marrow stromal
cells and regulated by G-CSF. (A) Bone marrow
endothelial cells (7AAD –CD45loTer119loCD31+) or
osteoblasts (7AAD–CD45loTer119loGFP+) were isolated by cell sorting from Col2.3:GFP transgenic mice.
Shown are representative dot plots depicting the sorting strategy. (B) Normalized gene chip signal at baseline for all chemokines with an average signal intensity of greater than 400 in at least 1 of the cell types.
When more than 1 probe set existed, the highest
signal was selected. Ppbp encodes for CXCL7, and
Mif is a nonchemokine ligand for CXCR2 and CXCR4
(60). (C) Expression of CXCR2 and CXCR4 ligands
in endothelial cells from WT mice at baseline or after
G-CSF administration. (D) CXCL2 protein in bone
marrow supernatant at baseline or after G-CSF, measured by ELISA (n = 4 mice per group). The dashed
line represents the limit of detection for the assay.
*P < 0.05; **P < 0.01; ***P < 0.001; 2-way ANOVA.

simple mechanism in which the absence of CXCR2 signals results
in neutrophil retention through increased CXCR4 expression.
To more directly assess the relationship between CXCR2 and
CXCR4 signals in the regulation of neutrophil trafficking, we
treated mixed chimeras with AMD3100, a small-molecule CXCR4
antagonist. At 1 hour after AMD3100 administration, a 3.8- ± 1.2fold increase in WT neutrophils in the blood was observed (Figure
4B). In contrast, no increase in Cxcr2–/– neutrophils in the blood
was observed, despite the fact that the majority of neutrophils
in the bone marrow 1 hour after AMD3100 administration were
of CXCR2–/– origin (Figure 4, B and C). Accordingly, the NDI for
Cxcr2–/– cells after AMD3100 administration was dramatically
lower than that of WT cells (0.53% ± 0.21% versus 13.0% ± 3.27%;
P = 0.02; Figure 4D), which suggests that neutrophil mobilizaThe Journal of Clinical Investigation

tion in response to transient CXCR4 inhibition is
dependent on CXCR2.
We previously reported that mice carrying a
myeloid-specific KO of CXCR4 (LysMCre/+Cxcr4fl/–;
referred to herein as MKO) displayed marked basal
neutrophilia (22). To study the genetic interaction
of the Cxcr2- and Cxcr4-null alleles, we crossed
MKO mice with the Cxcr2–/– mice to generate double-KO mice (LysMCre/+Cxcr2–/–Cxcr4fl/–; referred to
herein as DKO). Similar to the Cxcr2–/– and MKO
mice, DKO mice displayed marked neutrophilia
at baseline (data not shown). To examine the
cell-intrinsic properties of neutrophils lacking
both CXCR2 and CXCR4, mixed chimeras were
generated as described above using DKO or, as a
control, MKO bone marrow cells. Recipient mice
showed the expected level of donor engraftment
in the bone marrow, with 52.1% ± 4.8% (DKO) and
62.2% ± 2.3% (MKO) of B lymphocytes derived
from mutant cells. As expected, mixed chimeras
containing MKO cells showed a marked redistribution of Cxcr4–/– neutrophils into the blood (Figure 4, E and F). Surprisingly, a similar phenotype
was observed in DKO chimeras, which showed
that loss of CXCR2 signals cannot rescue the neutrophilic phenotype of CXCR4-deficient neutrophils.
To examine whether CXCR4 signals are required for mobilization by CXCR2 ligands, MKO mixed chimeras were given a single
injection of the CXCR2 agonist GROβ. Whereas the number of WT
neutrophils in the blood of MKO chimeras increased 3.8- ± 0.5-fold
30 minutes after GROβ administration, only a minimal increase in
Cxcr4–/– neutrophils was observed, which suggests that neutrophil
release induced by CXCR2 activation is at least partially dependent
on CXCR4 (Figure 4G). Collectively, these data showed that CXCR4
and CXCR2 antagonistically regulate neutrophil release from the
bone marrow, with CXCR4 playing a dominant role.
Expression of chemokines by osteoblasts and endothelial cells in the
bone marrow. Previous studies have established that bone marrow
stromal cells, in particular osteoblasts and endothelial cells, are
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the major source of CXCL12 in the bone marrow (21, 25, 27, 45,
47–50). However, the expression of other chemokines, specifically
ELR+ CXCR2 ligands, in bone marrow stromal cells is unknown.
To address this issue, we analyzed stromal cells from the bone
marrow of transgenic mice expressing GFP in osteoblast lineage cells (Col2.3-GFP; refs. 50, 51). Specifically, CD45loTer119lo
stromal cells were sorted into osteoblast and endothelial fractions (GFP+ and CD31+, respectively), which were then subjected
to RNA expression profiling (Figure 5A). Of note, expression
of endothelial- or osteoblast-specific genes was appropriately
enriched in the relevant cell fraction, demonstrating the fidelity
of our sorting strategy (Supplemental Tables 1 and 2; available
online with this article; doi:10.1172/JCI41649DS1). As reported
previously (27, 50), constitutively high expression of CXCL12
was observed in osteoblasts and endothelial cells, with higher
expression in osteoblasts (Figure 5B). CXCR2 ligands CXCL1
and CXCL2 were also constitutively expressed in osteoblasts and
endothelial cells, but with higher endothelial expression.
To examine the effect of G-CSF on chemokine expression in
the bone marrow microenvironment, endothelial cells were isolated from the bone marrow after G-CSF administration. Osteoblasts were not sorted, since their number is markedly reduced by
G-CSF (27, 48, 50, 52). Of note, there was no change in bone marrow endothelial cell number (D.C. Link, unpublished observation).
RNA expression profiling showed that CXCL2 expression in bone
marrow endothelial cells was induced 2.7- ± 0.3-fold by G-CSF,
whereas CXCL12 mRNA was modestly reduced to 47% ± 3% of its
basal level; other chemokines remained unchanged (Figure 5C).
Consistent with the mRNA data, CXCL2 protein was detected in
the bone marrow supernatant at baseline, with increased expression after G-CSF administration, although the difference was not
statistically significant (Figure 5D). Since osteoblast number is
markedly reduced after G-CSF administration, these data suggest
that the balance of expression in the bone marrow from proretention (CXCL12) to mobilizing chemokines (CXCL1 and CXCL2)
may contribute to neutrophil mobilization by G-CSF.
Discussion
In the present study, we generated Cxcr2–/– mixed bone marrow
chimeras to characterize the cell-intrinsic effect of CXCR2 deletion
on neutrophil trafficking from the bone marrow. We showed that
mature, occasionally hypersegmented, Cxcr2–/– neutrophils were
selectively retained in the bone marrow, reproducing a myelokathexis phenotype. In contrast, Cxcr2–/– mice displayed neutrophilia, suggesting augmented neutrophil production and/or release. Studies of
leukocyte adhesion deficiency (LAD) mice provide a potential explanation for these discrepant results. Similar to Cxcr2–/– mice, β2 integrin–deficient mice (Itgb2–/–), which reproduce LAD type I in humans,
exhibit impaired emigration of neutrophils from the circulation to
peripheral tissues and neutrophilia when housed under SPF conditions (34, 53). In a series of elegant experiments, Forlow et al. (54)
and Stark et al. (55) showed that, in Itgb2–/– mixed chimeras, as little
as 10% WT neutrophils was sufficient to restore normal neutrophil
homeostasis. Moreover, they showed that neutrophil emigration into
peripheral tissues initiated a negative feedback loop that suppresses
IL-17 and G-CSF production. Thus, the emigration defect shared by
Cxcr2–/– and Itgb2–/– neutrophils may disrupt this negative feedback
loop and lead to the production of stress cytokines that stimulate
granulopoiesis. Consistent with this possibility, serum levels of
IL-6 are elevated in both Cxcr2–/– and Itgb2–/– mice (34, 53).
2428
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Our results indicate that CXCR2 and CXCR4 coordinately
regulate neutrophil trafficking from the bone marrow. Previous
studies have demonstrated that treatment of neutrophils with
CXCR2 ligands results in impaired CXCR4 signaling through heterologous desensitization and/or internalization (43, 46), which
suggests that CXCR2 regulates neutrophil mobilization through
modulation of CXCR4 signaling and/or expression. Consistent
with this possibility, Martin et al. and others previously showed
that neutrophil mobilization by the CXCR2 chemokine CXCL1
was markedly increased by transient CXCR4 inhibition (42–44).
Conversely, Cxcr2–/– neutrophils displayed almost no mobilization in response to transient CXCR4 inhibition (Figure 4, B–D).
This surprising result suggests at least 2 possibilities: (a) loss of
CXCR2 may augment basal CXCR4 signaling, thereby rendering
cells resistant to AMD3100; and (b) CXCR2 signals may function independently of CXCR4 to direct neutrophil release after
AMD3100-induced CXCR4 blockade. In support of the first possibility, doubly deficient Cxcr2–/–Cxcr4–/– neutrophils displayed
constitutive mobilization (Figure 4, E and F), demonstrating that
CXCR2 signals are not required for neutrophil mobilization in the
complete absence of CXCR4 signals and suggesting a dominant
role for CXCR4 in the regulation of neutrophil trafficking from
the bone marrow. Consistent with this conclusion, the present
study and our previous report showed that neutrophil mobilization by the CXCR2 chemokine GROβ was impaired in the complete absence of CXCR4 signals (i.e., in Cxcr4–/– neutrophils; Figure 4G and ref. 22). Collectively, these data suggest that CXCR4
and CXCR2 signaling antagonistically regulate neutrophil release
from the bone marrow.
Previous studies have established that CXCL12 is constitutively
expressed by bone marrow stromal cells, including osteoblasts,
endothelial cells, and CXCL12-abundant reticular (CAR) cells
(21, 25, 27, 45, 47–50). Quantitative analysis of sorted stromal cell
populations suggested that osteoblasts are the major source of
CXCL12 in the bone marrow (27). Consistent with these findings,
our RNA expression profiling of sorted bone marrow endothelial
cells and osteoblasts demonstrated significantly higher expression of CXCL12 mRNA in osteoblasts. The expression profiling
data also showed that ELR+ CXC chemokines CXCL1, CXCL2, and
CXCL7 were constitutively expressed in bone marrow endothelial
cells and/or osteoblasts. However, in contrast to CXCL12, these
chemokines were expressed at higher levels in endothelial cells.
Of note, we were unable to convincingly detect CXCL1 or CXCL2
protein expression by immunostaining of bone marrow sections;
thus, it is possible that other cell populations in the bone marrow may be a source of these chemokines. Together, the data suggest a tug-of-war model wherein endothelial-derived chemokines
(primarily CXCR2 ligands) direct neutrophil chemotaxis toward
the vasculature for entry into the circulation, while endosteal
osteoblasts produce chemokines (primarily CXCL12) that promote neutrophil retention (Figure 6). Under basal conditions, the
balance of chemokine production favors neutrophil retention in
the bone marrow. Under stress conditions, expression of inflammatory cytokines, most notably G-CSF, is increased (56). We and
others previously showed that G-CSF administration is associated
with marked suppression of endosteal osteoblasts (27, 48, 50, 52).
In addition, we showed here that CXCL2 expression increased in
bone marrow endothelial cells after G-CSF administration. The
net effect is a shift in the balance of chemokine production to the
endothelium, thereby promoting neutrophil release from the bone
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phils + bone marrow neutrophils + spleen neutrophils). Bone marrow
extracellular fluid was obtained by sequentially flushing both femurs
with 400 μl ice-cold PBS and harvesting the supernatant after pelleting
cells by centrifugation at 400 g for 2 minutes.
Flow cytometry. Cells were stained by standard protocols with the following antibodies (eBiosciences unless otherwise noted): Chimerism
was assessed using PerCP-Cy5.5–conjugated Ly5.1 (CD45.1), allophycocyanin-conjugated (APC-conjugated) Ly5.2 (CD45R.2), and 1 or more of
the following lineage markers: FITC-conjugated Ly6G (Gr-1, myeloid),
PE-conjugated CD3e (T lymphocytes), and APC-efluor780–conjugated
CD45R (B220, B lymphocytes). A lineage cocktail of FITC-conjugated
Gr-1, B220, CD3e, and Ter119 (erythroid) was used to sort progenitor
cells. CXCR4 expression was assessed by incubating with anti-CD16/32
(Fc-block; BD Biosciences) and biotin-conjugated CXCR4 (BD) followed
Figure 6
by PE-conjugated streptavidin. Isotype-matched antibodies were used as
Tug-of-war model of neutrophil trafficking from the bone marrow. See Disnegative controls. Data were collected on a FACScan 5-color, 2-laser flow
cussion for details.
cytometer (BD Biosciences and Cytek Development) using Cellquest software (BD) and analyzed with the FlowJo software package (Tree Star).
Bone marrow leukocyte morphology. WT or Cxcr2–/– bone marrow cells
marrow. Confirmation of this model will require demonstration were isolated using a Reflection high-speed cell sorter (i-Cyt). Manual leuthat CXCL2 ligands produced by endothelial cells directly contrib- kocyte differentials were performed in a blinded fashion on Wright-stained
ute to neutrophil mobilization from the bone marrow.
cytospins prepared by cytocentrifugation of 200,000 sorted cells at 18 g for
In summary, this study provides evidence that ELR+ CXCR2 4 minutes. Photomicrographs were acquired using an E plan ×100/1.25 NA
ligands are a second chemokine family that, together with oil immersion objective, Microphot SA microscope, Digital Sight DS-Fi1
CXCL12, controls neutrophil trafficking from the bone marrow. camera, and NIS-Elements F2.30 software (all from Nikon); conversion from
Although most cases of WS are associated with autosomal-domi- color to black and white was done using Photoshop CS3 (Adobe Systems).
nant, gain-of-function mutations in CXCR4, several pedigrees have
Colony-forming cell assay. Linlo WT or Cxcr2–/– bone marrow cells were isobeen reported that lack the characteristic mutations (9, 11, 14). lated using a Reflection high-speed cell sorter, and 350 (CFU in culture)
Balabanian and colleagues reported a WS pedigree with decreased or 3,000 (CFU-granulocyte) sorted cells were plated in 2.75 ml methylexpression of GPCR kinase-3 (GRK3), a protein that negatively cellulose media supplemented with a cocktail of recombinant cytokines
regulates CXCR4 signaling (57). Recently, homozygous loss-of- or 10 ng/ml recombinant human G-CSF (MethoCult 3434 or 3231,
function mutations in CXCR2 have been identified in a pedigree respectively; Stemcell Technologies). Duplicate cultures were incubated
with isolated myelokathexis (A.L. O’Shaughnessy, Q. Sun, and G.A. at 37°C for 14 days, after which colonies containing at least 100 cells
Diaz, unpublished observations). Our data provide experimental were counted in a blinded fashion.
evidence that loss-of-function mutations in Cxcr2 are sufficient
Neutrophil mobilization. Recombinant human G-CSF (Amgen) was adminto induce a myelokathexis phenotype in mice. Of potential clini- istered by twice-daily subcutaneous injection at a dose of 125 μg/kg/d for
cal relevance for the treatment of patients with myelokathexis and 5 days. Mice were analyzed 3–4 hours after the final injection on day 5.
Cxcr2 mutations, our studies of Cxcr2–/– neutrophils suggest that AMD3100 (Sigma-Aldrich) or recombinant human GROβ (Genzyme), was
mobilization responses to AMD3100 or G-CSF may be impaired.
administered as a single subcutaneous injection at doses of 5 mg/kg and
100 μg/kg, respectively. Peripheral blood was obtained within 90 minutes
Methods
prior to and 1–2 hours after the first injection.
Mice. Sex- and age-matched congenic C57BL/6 Cxcr2–/– (Jackson LaboStromal cell chemokine expression profiling. Groups of 10 Col2.3-GFP or WT
ratory; refs. 34, 58), LysMCre/+Cxcr4fl/– (22), pOBCol2.3-GFP (gift from mice were either left untreated or given G-CSF or vehicle for 7 days as indiD. Rowe, University of Connecticut, Farmington, Connecticut, USA; cated. To isolate stromal cells, femurs were serially digested with collageref. 51), and WT mice that have the Ly5.1 gene (B6.SJL-Ptprc* Pep3b BoyJ; nase (Worthington Biochemical) as previously reported (50, 52). Stromal
Jackson Laboratory) were maintained under SPF conditions according to cells were then incubated with APC-conjugated CD45, APC-conjugated
methods approved by the Washington University Animal Studies Com- Ter119, and PE-conjugated CD31 (PECAM-1). 7-Amino-Actinomycin D
mittee. All transgenic strains had been backcrossed at least 10 generations (7AAD) was used to exclude nonviable cells. An average of 20,000 cells was
onto a C57BL/6 background.
sorted directly into TRIzol LS reagent (Invitrogen), and RNA was isolated
Bone marrow transplantation. Bone marrow cells from WT Ly5.1-express- according to the manufacturer’s instructions. RNA was amplified, proing mice and Cxcr2–/–, MKO (LysMCre/+Cxcr4fl/–), or DKO (LysMCre/+Cxcr2–/– cessed, and hybridized to Affymetrix MOE430v2.0 GeneChip microarrays
Cxcr4fl/–) mice (Ly5.2 expressing) were mixed at a 1:1 ratio, and a total of per protocols of the Siteman Cancer Center Multiplexed Gene Analysis
2 × 106 cells injected retro-orbitally into lethally irradiated (1,000 cGy) WT Core Facility. After passing quality control, array data were normalized,
recipient mice. Antibiotics (trimethoprim-sulfamethoxazole, Alpharma) annotated, and deposited at the Siteman Cancer Center Bioinformatics
were given for 2 weeks after transplant.
Core Facility according to standard protocols. Expression data for all
Blood, bone marrow, and spleen analysis. Blood, bone marrow, and spleen known chemokines, obtained from at least 4 independent cell sorting
cells were quantified using a Hemavet automated cell counter (CDC Tech- experiments, were analyzed and compared using 2-way ANOVA.
nologies). Absolute neutrophil numbers were calculated assuming a blood
CXCL2 ELISA. Quantification of CXCL2 protein in bone marrow
volume of 1.8 ml and a whole femur equivalent to 6% of the total bone mar- extracellular fluid was performed using a commercially available ELISA
row (59). NDI was calculated as follows: blood neutrophils/(blood neutro- kit from Peprotech according to the manufacturer’s instructions.
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Statistics. Significance was determined using Prism software (GraphPad). Statistical significance of differences was calculated using 2-tailed
Student’s t tests (assuming equal variance) or, where indicated, 1- or 2-way
ANOVA with Bonferroni post-testing. P values less than 0.05 were considered significant. All data are presented as mean ± SEM.
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